

**Round table discussion:**

***" Challenges and Opportunities in PROTAC vs Small Molecules Development"***

**Panelist:**

Dr Georg Winter (Research Center for Molecular Medicine of the Austrian Academy of Sciences, Austria)



Georg Winter, PhD, obtained his degree from the Medical University of Vienna, working on elucidating the mechanism of action of anti-neoplastic drugs. He continued his training in chemical biology, working as a postdoc with James Bradner at Harvard. There, he innovated the first generalizable pharmacologic solution to in vivo target protein degradation. He was recruited as a CeMM PI in 2016 where his research is now focused on using the unique molecular pharmacology of targeted protein degradation to understand and disrupt fundamental principles of gene control in cancer. Georg (co-) authored 35 manuscripts including publications in *Science*, *Nature*, *Nature Chemical Biology*, *Nature Genetics* and *Molecular Cell*. His interdisciplinary research lab is supported by several national and international grants and fellowships including an ERC Starting

Grant. Dr. Winter's contribution to the field of targeted protein degradation was acknowledged via multiple prizes and awards, including the prestigious Eppendorf Award 2019 and the Elisabeth Lutz Award of the Austrian Academy of Sciences.